You are here

Article Text

Article menu
Download PDFPDF
Letters
Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease
  1. E Hachulla1,
  2. A Wibaux1,
  3. P-Y Hatron1,
  4. U Michon-Pasturel1,
  5. V Queyrel1,
  6. A-L Fauchais1,
  7. B Devulder1,
  8. M-N Lefebvre2,
  9. M Yilmaz2
  1. 1Internal Medicine Department, Hôpital Claude Huriez, University of Lille, 59037 Lille cedex, France
  2. 2Central Pharmacy, University of Lille
  1. Correspondence to:
    Professor E Hachulla, Internal Medicine Department, Hôpital Claude Huriez, University of Lille, 59037 Lille cedex, France;
    ehachulla{at}chru-lille.fr

https://doi.org/10.1136/ard.61.3.277-a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The high cost of IV immunoglobulins is often considered to be a disadvantage of this treatment. However, this does not take into account the benefits gained—for example, the savings achieved in the costs of corticosteroids and immunosuppressive drugs and, above all, the improvement in quality of life achieved through functional improvement, as noticed in inflammatory myopathies and Still's disease.1–,3 It is precisely to minimise the costs of IV immunoglobulin treatments and to enable patients to remain at home that we have developed the administration of IV immunoglobulins at home when sequential treatments are necessary.

    Between January 1995 and March 2000 30 patients (18 women, 12 men) were enrolled, with a mean (SD) age of 44 (0.9) for the women and 51 (0.9) years for the men (range 21–74). All the patients had …

    View Full Text